Physician

Adeyinka Abimbola Adegoroye, MB CHB

According to 2025 Medicare claims, Adeyinka Adegoroye, MB CHB (NPI: 1952500423) practices nephrology in the Greensboro-High Point, NC market, with the plurality of this provider's patient population coming from Guilford, NC. This provider's primary affiliated billing organization is HIGH POINT NEPHROLOGY ASSOCIATES, PC (NPI: 1639118607; TIN: 203404076) and primary practice location at 27262-4331.

Adegoroye's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 164 traditional Medicare patients, billed 809 HCPCS/CPT codes, and received $65,801 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,881 prescription claims across 273 beneficiaries totaling $132,729 in drug costs, led by Lokelma (Sodium Zirconium Cyclosilicate). DME data shows 125 claims. Open Payments data shows 10 records totaling $320. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $134,782 to $65,801. Similarly, Part D prescription costs have declined steadily, from $209,081 to $132,729. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,939 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	317	1,317	$134,782
2016	330	1,415	$142,449
2017	324	1,377	$139,121
2018	315	1,459	$157,432
2019	327	1,527	$163,529
2020	313	1,503	$166,484
2021	274	1,201	$149,758
2022	210	1,058	$111,701
2023	168	720	$73,171
2024	164	809	$65,801

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	263	2,336	$209,081
2016	272	2,559	$294,478
2017	254	2,260	$308,583
2018	272	2,130	$180,994
2019	304	2,254	$188,643
2020	305	2,250	$160,823
2021	302	2,478	$212,112
2022	292	2,178	$164,948
2023	268	1,897	$179,330
2024	273	1,881	$132,729

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	153	$11,600
2016	N/R	337	$85,492
2017	N/R	169	$11,135
2018	N/R	32	$746
2019	N/R	76	$1,671
2020	N/R	118	$3,179
2021	N/R	207	$7,019
2022	N/R	80	$2,764
2023	N/R	71	$1,549
2024	N/R	125	$2,236

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	23	65	$231
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	45	63	$120
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	66	144	$74
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	72	241	$55
90935	Hemodialysis procedure with physician evaluation	28	111	$50

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lokelma	Sodium Zirconium Cyclosilicate	58	1,997	$27,054
Myrbetriq	Mirabegron	25	1,110	$16,554
Veltassa	Patiromer Calcium Sorbitex	15	745	$13,205
Sevelamer Carbonate	Sevelamer Carbonate	61	2,397	$5,004
Calcium Acetate	Calcium Acetate	41	1,915	$2,976

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	24	$705
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	40	$564
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	25	$545
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	24	$414
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	12	$8

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$320	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adeyinka Abimbola Adegoroye, MB CHB?

Tedicare shows public-source Medicare data for Adeyinka Abimbola Adegoroye, MB CHB (NPI 1952500423), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adeyinka Abimbola Adegoroye, MB CHB have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adeyinka Abimbola Adegoroye, MB CHB?

Adeyinka Abimbola Adegoroye, MB CHB is linked to HIGH POINT NEPHROLOGY ASSOCIATES, PC (billing NPI 1639118607) in the available physician profile data.

Does Adeyinka Abimbola Adegoroye, MB CHB have Open Payments data?

Adeyinka Abimbola Adegoroye, MB CHB has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.